Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-05, Stock:LLY, The news for the past five days is as follows:
2018-09-28: NEWS1: Tesla and More Mark End of Quarte; FDA OKs Lilly's Migraine Drug -- ICYMI.NEWS2: Winners and losers for Friday, September 28th.NEWS3: Health Care Sector Update for 09/28/2018: LLY,SPRO,CCXI,ALDX.NEWS4: Health Care Sector Update for 09/28/2018: LLY,SPRO,CCXI,ALDX.NEWS5: Teva Announces First-to-File Launch of Generic Cialis.NEWS6: Sanofi Stock Up 2.8% in September: What Lies Ahead?.NEWS7: A Look at Eli Lilly’s Revenue Growth Rate.NEWS8: Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers.NEWS9: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS10: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS11: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS12: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS13: Sanofi Stock: How Much Upside Potential Does Wall Street See?.NEWS14: What’s Eli Lilly’s Valuation as of September 27?.NEWS15: Stocks - Tesla Tumbles in Pre-market; Eli Lilly, BlackBerry Gain.NEWS16: Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality.NEWS17: Eli Lilly’s Stock Performance in September.NEWS18: Lilly Bio-Medicines president on new Emgality migraine dr....NEWS19: Google CEO in DC, Eli Lilly gets green light, Boeing wins big.NEWS20: Top Research Reports for Alphabet, Bank of America & PepsiCo.NEWS21: Comparing Pfizer Stock and Merck and Co. Stock.NEWS22: Google CEO in DC, Eli Lilly gets green light, Boeing wins big.NEWS23: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS24: Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags.NEWS25: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results.NEWS26: Technical Indicators for Pfizer Stock’s Movements.NEWS27: U.S. FDA approves Lilly migraine drug; price same as rivals.NEWS28: Eli Lilly Migraine Drug Approved and Will Be Free to Patients.NEWS29: Eli Lilly Migraine Drug Approved and Will Be Free to Patients.
2018-10-01: NEWS1: Do You Know Who Else Invests In Eli Lilly and Company (NYSE:LLY)?.NEWS2: Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?.NEWS3: How GlaxoSmithKline’s Pharmaceutical Business Performed.NEWS4: Eli Lilly’s Earnings Quality and Dividend Performance.NEWS5: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS6: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS7: Eli Lilly’s Market Cap and Shareholding Pattern.NEWS8: Comparing Pfizer Stock and Eli Lilly Stock.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS10: The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical.NEWS11: Assessing Eli Lilly’s Latest Performance by Segment.
2018-10-02: NEWS1: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS2: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS3: Examining the Performances of Eli Lilly’s Oncology Products.NEWS4: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS5: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS6: How Eli Lilly’s Cardiovascular Products Have Been Faring.NEWS7: Migraine sufferers: Help is on the way from 3 new drugs, but they’ll cost $6,900 a year.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: Stocks making the biggest move premarket: PEP, AMZN, SFIX, CVX & more.NEWS10: Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?.NEWS11: A Closer Look at Eli Lilly’s Human Pharmaceutical Business.NEWS12: Eli Lilly's diabetes treatment meets main goal in two late-stage studies.NEWS13: Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes.NEWS14: Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint.NEWS15: Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint.
2018-10-03: NEWS1: Lilly Confirms Date and Conference Call for Third-Quarter 2018 Financial Results Announcement.NEWS2: Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies.NEWS3: Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies.NEWS4: Eli Lilly&apos;s Ultra Rapid Lispro Succeeds in Diabetes Studies.NEWS5: Merck & Other Pharma Players Await FDA Decisions in October.NEWS6: Merck & Other Pharma Players Await FDA Decisions in October.NEWS7: A Look at Elanco, Eli Lilly’s Animal Health Business.NEWS8: The hidden dangers of testosterone replacement therapy you should know about.NEWS9: How Have Eli Lilly’s Endocrine Products Been Performing?.NEWS10: The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares.
2018-10-04: NEWS1: Alphabet and Simon Property skid while Constellation rises.NEWS2: Tech Stocks Punished As Nasdaq Breaks Support; Leading Software Stocks Nailed.NEWS3: Notable Thursday Option Activity: HD, LLY, ADBE.NEWS4: Notable Thursday Option Activity: HD, LLY, ADBE.NEWS5: US STOCKS-Wall St succumbs to soaring bond yields.NEWS6: XLV, UNH, MDT, LLY: ETF Inflow Alert.NEWS7: XLV, UNH, MDT, LLY: ETF Inflow Alert.NEWS8: Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial.NEWS9: S&P 500 Movers: COTY, LLY.NEWS10: S&P 500 Movers: COTY, LLY.NEWS11: Amgen’s Stock Performance and Estimates after Q3 2018.NEWS12: US STOCKS-Wall St succumbs to soaring bond yields.NEWS13: Lilly's diabetes drug data impresses, hurts rival Novo's shares.NEWS14: US STOCKS-Wall St set to open lower as Treasury yields jump.NEWS15: Diabetes Drug&apos;s Results Push Lilly to Look at Obesity Too.NEWS16: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut.NEWS17: Eli Lilly&apos;s stock surges toward record after positive trials for diabetes treatments.NEWS18: Eli Lilly’s Stock Performance and Estimates for Q3 2018.NEWS19: Mylan Launches Its Generic Brevibloc Injection.NEWS20: Global Markets Drag Stocks Lower; Did China Hack Apple?.NEWS21: Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes.NEWS22: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes.NEWS23: Eli Lilly's diabetes drug shows promise in mid-stage trial.NEWS24: Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint.NEWS25: Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint.

Answer: Rise